Hervolution will be presenting at Biotech Showcase 2020

Please meet us at the 2020 Biotech Showcase in San Francisco, where Inprother CBO, Dr. Mathias Kroll will be presenting Hervolution.   The presentation will take place at 10.00AM January 4th 2020 at:   Hilton San Francisco Union Square 333 O’Farrell Street – Ballroom Level San Francisco, CA 94102

Steven Glazer joins Hervolution as Medical Advisor

Steven Glazer has many years of international experience in healthcare and biotechnology. He has held a number of senior positions within pharmaceutical and bioengineering companies in Europe and the US, including Novo Nordisk, Zealand Pharma, BioInvent International and  Hansa Medical, and has gained deep knowledge of pharmaceutical development involving medical and regulatory planning. Steven’s current assignments […]

Hervolution presentation by Peter J. Holst

Hervolution treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where Hervolution is presented by Associate Professor Peter Johannes Holst.

Hervolution research published in Oncotarget

We are very happy to announce that a new scientic article by the Inprother-team has been accepted in the Oncotarget journal. The article: “Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice by Lasse Neukirch, Tea Kirkegaard Nielsen, Henriette Laursen, Joana Daradoumis, Christian Thirion and Peter Johannes Holst For more info: […]

Hervolution got investment by Novo Nordisk Foundation

Hervolution is one of the three companies to join the BII Creation House program run by Novo Nordisk Foundation. After a successful Business Acceleration Academy, Hervolution was recommended for the program by an external committee and approved by the BII Board of Directors. In the coming 18 months, Inprother will be part of BioInnovation Institute […]